Key Considerations for ADAPs’ Addition of Hepatitis C Treatment to Formularies

NASTAD continues work to ensure that individuals co-infected with HIV and hepatitis C virus (HCV) can gain access to curative treatments for HCV via AIDS Drug Assistance Programs (ADAPs).  While the number of ADAPs that include one or more direct-acting antiviral (DAA) HCV treatments on their formulary continues to increase, many ADAPs still face challenges in justifying such additions to their coverage offerings. To support ADAPs regarding HCV DAA inclusion on formularies, NASTAD has collated the following key considerations based on the experiences of ADAPs that have successfully expanded their formularies to include HCV DAAs.